Punt C J, de Vries I J, Mulders P F, Adema G J, Figdor C G
Afd. Medische Oncologie, Academisch Ziekenhuis St. Radboud, Nijmegen.
Ned Tijdschr Geneeskd. 1999 Nov 27;143(48):2408-14.
Dendritic cells are among the most efficient antigen-presenting cells of our immune system and they play a crucial role in immunity reactions such as the activation of T and B cells and the induction or maintenance of tolerance. New culture methods allow us to generate dendritic cells in sufficient numbers for further studies and for the preparation of antigen-loaded dendritic cells for clinical application in cancer patients. In animal studies immunization with antigen-loaded dendritic cells offered protection from growth of injected tumour cells. In experimental clinical studies in cancer patients with e.g. metastatic renal carcinoma, melanoma and B cell lymphoma some lasting remissions were observed after administration of antigen-loaded dendritic cells. Side effects were minor. Unanswered questions on tumour vaccines with antigen-loaded dendritic cells concern specific matters, such as optimal culture methods and antigen loading, and general matters, such as dose, frequency, duration and route of administration. Also, no method is currently available by which the in vivo immune response can be measured accurately.
树突状细胞是我们免疫系统中最有效的抗原呈递细胞之一，它们在免疫反应中发挥着关键作用，如激活T细胞和B细胞以及诱导或维持耐受性。新的培养方法使我们能够产生足够数量的树突状细胞用于进一步研究，以及制备用于癌症患者临床应用的负载抗原的树突状细胞。在动物研究中，用负载抗原的树突状细胞进行免疫可提供针对注射肿瘤细胞生长的保护。在针对例如转移性肾癌、黑色素瘤和B细胞淋巴瘤患者的实验性临床研究中，给予负载抗原的树突状细胞后观察到了一些持久的缓解。副作用较小。关于负载抗原的树突状细胞肿瘤疫苗的未解决问题涉及特定事项，如最佳培养方法和抗原负载，以及一般事项，如剂量、频率、持续时间和给药途径。此外，目前尚无能够准确测量体内免疫反应的方法。
